303 related articles for article (PubMed ID: 14704032)
1. Molecular pharmacodynamics in childhood leukemia.
Pieters R; den Boer ML
Int J Hematol; 2003 Dec; 78(5):402-13. PubMed ID: 14704032
[No Abstract] [Full Text] [Related]
2. Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Vizirianakis IS; Chatzopoulou M; Bonovolias ID; Nicolaou I; Demopoulos VJ; Tsiftsoglou AS
J Med Chem; 2010 Oct; 53(19):6779-810. PubMed ID: 20925433
[No Abstract] [Full Text] [Related]
3. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
4. miR-138 might reverse multidrug resistance of leukemia cells.
Zhao X; Yang L; Hu J; Ruan J
Leuk Res; 2010 Aug; 34(8):1078-82. PubMed ID: 19896708
[TBL] [Abstract][Full Text] [Related]
5. The leukemia stem cell.
Estrov Z
Cancer Treat Res; 2010; 145():1-17. PubMed ID: 20306242
[No Abstract] [Full Text] [Related]
6. Resistance to apoptosis induced by serum depletion and all-trans retinoic acid in drug-resistant leukemic cell lines.
Kakihara T; Fukuda T; Kamishima T; Naito M; Tanaka A; Uchiyama M; Kishi K
Leuk Lymphoma; 1997 Jul; 26(3-4):369-76. PubMed ID: 9322900
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activation of wild-type p53 in the therapy of leukemia.
Kojima K; Ishizawa J; Andreeff M
Exp Hematol; 2016 Sep; 44(9):791-798. PubMed ID: 27327543
[TBL] [Abstract][Full Text] [Related]
9. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
[TBL] [Abstract][Full Text] [Related]
10. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
11. Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
Malek SN; Gore SD
Leuk Res; 2003 Jan; 27(1):1-3. PubMed ID: 12479845
[No Abstract] [Full Text] [Related]
12. Stromal cells attenuate the cytotoxicity of imatinib on Philadelphia chromosome-positive leukemia cells by up-regulating the VE-cadherin/β-catenin signal.
Chen C; Zhang HX; Wang M; Song XG; Cao J; Wang L; Qiao JL; Lu XY; Han ZX; Zhu P; Pan B; Wu QY; Zhao K; Yan ZL; Li ZY; Zeng LY; Xu KL
Leuk Res; 2014 Dec; 38(12):1460-8. PubMed ID: 25443888
[TBL] [Abstract][Full Text] [Related]
13. FLT3 tyrosine kinase as a target in acute leukemias.
Griffin JD
Hematol J; 2004; 5 Suppl 3():S188-90. PubMed ID: 15190306
[No Abstract] [Full Text] [Related]
14. MicroRNAs in leukemia.
Croce C
Clin Adv Hematol Oncol; 2006 Aug; 4(8):577-8. PubMed ID: 17099614
[No Abstract] [Full Text] [Related]
15. Targeting c-myc in leukemia.
Calabretta B; Skorski T
Anticancer Drug Des; 1997 Jul; 12(5):373-81. PubMed ID: 9236853
[No Abstract] [Full Text] [Related]
16. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
[TBL] [Abstract][Full Text] [Related]
17. The role of XIAP in resistance to TNF-related apoptosis-inducing ligand (TRAIL) in Leukemia.
Saraei R; Soleimani M; Movassaghpour Akbari AA; Farshdousti Hagh M; Hassanzadeh A; Solali S
Biomed Pharmacother; 2018 Nov; 107():1010-1019. PubMed ID: 30257312
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species contribute to TRAIL receptors upregulation; the mechanism for PH II-7 augmenting TRAIL induced apoptosis in leukemia cells.
Peng H; Yuan X; Luo S; Li F; Wei X; Ye Z; Xiong D
Eur J Pharmacol; 2015 Jan; 746():344-52. PubMed ID: 25446561
[TBL] [Abstract][Full Text] [Related]
19. Pim-1 expression and monoclonal antibody targeting in human leukemia cell lines.
Li J; Hu XF; Loveland BE; Xing PX
Exp Hematol; 2009 Nov; 37(11):1284-94. PubMed ID: 19703513
[TBL] [Abstract][Full Text] [Related]
20. Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.
Kettyle LM; Liberante FG; Thompson A
Methods Mol Biol; 2014; 1196():349-70. PubMed ID: 25151174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
